Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Advanced Renal Cell Carcinoma |
Dose: by mouth – 800 mg Frequency: once daily Note: Take on empty stomach |
|
Indication: Soft Tissue Sarcomas |
Dose: by mouth – 800 mg Frequency: once daily Note: Take on empty stomach |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: Not indicated Note: Safety and efficacy not established; not indicated for use in pediatric patients |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Not Specified – Dosage not specified Note: Renal impairment: No dosage adjustment required |
Administration
- Take on empty stomach
- Take 1 hour before or 2 hours after meals
Side Effect
- ALT (SGPT) level raised (all grades 53%, grade 3 10%, grade 4 2%)
- AST/SGOT level raised (all grades 53%
- grade 3 7%
- grade 4 less than 1%)
- Diarrhea (52%)
- Increased glucose (41%)
- Hypertension (40%)
- Hair depigmentation (38%)
- Leukopenia (all grades 37%
- grade 3 0%
- grade 4 0%)
- Increased bilirubin level (all grades 36%
- grade 3 3%
- grade 4 less than 1%)
- Neutropenia (all grades 34%
- grade 3 1%
- grade 4 less than 1%)
- Phosphorous decreased (34%)
- Thrombocytopenia (all grades 32%
- grade 3 less than 1%
- grade 4 less than 1%)
- Lymphocytopenia (all grades 31%
- grade 3 4%
- grade 4 less than 1%)
- Sodium decreased (31%)
- Magnesemium decreased (26%)
- Nausea (26%)
- Weakness (22%)
- Vomiting (21%)
- Anorexia (22%)
- Fatigue (19%)
- Bradycardia (19%)
- Hemorrhage (all grades 13% to 16%
- grade 3 to 5 2%)
- Myocardial dysfunction (ie More than 15% decline in LVEF from baseline or ≥10% with baseline below normal) (11-13%)
- Abdominal pain (11%)
- Headache (10%)
- Proteinuria (9%)
- Weight loss (9%)
- Alopecia (8%)
- Dysgeusia (8%)
- Rash (8%)
- Hypothyroidism (4% to 7% )
- Palmar-plantar erythrodysesthesia (6%)
- Chest pain (5%)
- Dyspepsia (5%)
- Skin depigmentation (3%)
- Prolonged QT interval (Less than 2%)
- Hepatotoxicity (1%-2%)
- Facial edema (1%)
- Rectal hemorrhage (1%)
- Transient ischemic attack (1%)
- Hemorrhagic death (0.9%-1%)
- Cardiac dysfunction (eg decreased LVEF CHF) (0.6%)
- Congestive heart failure (0.5%)
- Torsades de pointes
- Cerebrovascular accident
- Pancreatitis
- Myocardial infarction
- Gastrointestinal fistula
- Gastrointestinal perforation
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
CYP3A4 inhibitors, P-gp & BCRP inhibitors, High-/low-fat food
|
Increases exposure & concentration of pazopanib
|
|
CYP3A4 inducers
|
May decrease plasma pazopanib concentration
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general drug reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store below 30° C in a cool and dry place, away from sunlight. Keep out of reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.